AI Science Tracker
EN

Predicting benefit from immune checkpoint inhibitors in patients with non-small-cell lung cancer by CT-based ensemble deep learning: a retrospective study

Department of Imaging Physics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA · 31 May 2023 · medicine

Discovery

Predicting benefit from immune checkpoint inhibitors in patients with non-small-cell lung cancer by CT-based ensemble deep learning: a retrospective study

Source check: Source checked. Not independent scientific confirmation.

Finding / tested result: An ensemble of four CT-based deep-learning subnetworks predicts progression-free and overall survival after immune-checkpoint inhibition in metastatic NSCLC, compared with conventional clinical/radiological risk models and external cohorts. The result is limited to the reported study population and evaluation; the source does not establish transfer to other populations or improved clinical outcomes.

Technology: Ensemble of four CT-based deep-learning subnetworks

Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.

AI contribution
Ensemble of four CT-based deep-learning subnetworks
Limitation / still unknown
The study does not establish improved patient outcomes or generalization beyond the evaluated setting.
Evidence sources and annotation context

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

Evidence sources: https://europepmc.org/article/MED/37268451 · https://doi.org/10.1016/s2589-7500(23)00082-1 · https://eutils.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&id=37268451&retmode=xml · https://pubmed.ncbi.nlm.nih.gov/37268451/

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: paper. Paper: linked separately.

Review date: 22 Nov 2026. Review scope: Primary result-bearing material for the stated method, result and evaluation, with bibliographic version information..

No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.

Editorial assessment: Impact 2/5 · Validation 2/5 · Novelty 2/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Open in the full catalog for filters, charts and related discoveries. Browse medicine discoveries.